QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:HSGX

Histogenics - HSGX Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$2.72
$2.90
50-Day Range
$0.16
$3.07
52-Week Range
$0.08
$1.43
Volume
4.56 million shs
Average Volume
9.06 million shs
Market Capitalization
$269.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
HSGX stock logo

About Histogenics (NASDAQ:HSGX) Stock

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive HSGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter.

HSGX Stock News Headlines

3 Dividend Stocks Perfect for Retirees - Nasdaq
Company News for Dec 23, 2020 - Yahoo Finance
See More Headlines

Receive HSGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter.

HSGX Company Calendar

Last Earnings
8/09/2018
Today
8/09/2022

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSGX
Fax
N/A
Employees
49
Year Founded
N/A

Profitability

Net Income
$-8,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.01) per share

Miscellaneous

Free Float
N/A
Market Cap
$269.61 million
Optionable
Not Optionable
Beta
3.10

Key Executives

  • Mr. Adam D. Gridley (Age 47)
    Interim Pres, CEO Treasurer, Sec., Consultant & Director
  • Mr. Jonathan I. Lieber (Age 49)
    Interim Chief Financial Officer
  • Mr. Stephen R. Kennedy (Age 62)
    Consultant













HSGX Stock - Frequently Asked Questions

How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) released its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.10.

What other stocks do shareholders of Histogenics own?

When did Histogenics IPO?

(HSGX) raised $60 million in an initial public offering on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

What is Histogenics' stock symbol?

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

What is Histogenics' stock price today?

One share of HSGX stock can currently be purchased for approximately $2.85.

How much money does Histogenics make?

Histogenics (NASDAQ:HSGX) has a market capitalization of $269.61 million. The biotechnology company earns $-8,640,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does Histogenics have?

Histogenics employs 49 workers across the globe.

How can I contact Histogenics?

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The official website for the company is www.histogenics.com. The biotechnology company can be reached via phone at 781-547-7900 or via email at investorrelations@histogenics.com.

This page (NASDAQ:HSGX) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.